Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending December 2013. The report details a specific share repurchase transaction executed on December 3, 2013, under authority granted by shareholders at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 620,000 Ordinary Shares of 25 pence each.
- Purchase Price Range: Highest price paid was 1,619.00 pence per share; lowest price paid was 1,610.00 pence per share.
- Treasury Holdings (Settled): 511,355,909 shares, representing 9.52% of total issued share capital.
- Treasury Holdings (Including Unsettled): 513,766,909 shares, representing 10.57% of total voting rights.
- Shares in Issue (Excluding Treasury): 4,860,409,937 shares.
Material Changes
The filing reports an increase in the Company's treasury share holdings following the purchase of 620,000 shares. Consequently, the percentage of total voting rights held in treasury increased to 10.57% when including unsettled shares. No other material changes to operations or financial position are disclosed in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure regarding share buybacks and voting rights calculations under the Financial Conduct Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total number of shares in issue (4,860,409,937) to confirm the denominator for calculating shareholder interest thresholds.
- Confirm the current percentage of voting rights held in treasury (10.57% including unsettled shares) to assess potential dilution or buyback program progress.
- Note that this filing does not contain operational or financial performance data; refer to the Company's Form 20-F or interim reports for revenue and profit metrics.